NO20003372L - Erytropoietinderivater - Google Patents

Erytropoietinderivater

Info

Publication number: NO20003372L
Authority: NO; Norway
Prior art keywords: erythropoietin derivatives; erythropoietin; derivatives
Prior art date: 1999-07-02

Application number

NO20003372A

Other languages

English (en)

Other versions

NO20003372D0 (no

NO327043B1 (no

Inventor

Pascal Sebastian Bailon

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-02

Filing date

2000-06-28

Publication date

2001-01-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003372(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2000-06-28 Publication of NO20003372D0 publication Critical patent/NO20003372D0/no

2001-01-03 Publication of NO20003372L publication Critical patent/NO20003372L/no

2009-04-06 Publication of NO327043B1 publication Critical patent/NO327043B1/no

Links

OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Oncology (AREA)
Virology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO20003372A 1999-07-02 2000-06-28 Konjugat, preparat samt anvendelse derav og fremgangsmate for fremstilling. NO327043B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US14225499P	1999-07-02	1999-07-02
US15022599P	1999-08-23	1999-08-23
US15154899P	1999-08-31	1999-08-31
US16615199P	1999-11-17	1999-11-17

Publications (3)

Publication Number	Publication Date
NO20003372D0 NO20003372D0 (no)	2000-06-28
NO20003372L true NO20003372L (no)	2001-01-03
NO327043B1 NO327043B1 (no)	2009-04-06

Family

ID=27495518

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20003372A NO327043B1 (no)	1999-07-02	2000-06-28	Konjugat, preparat samt anvendelse derav og fremgangsmate for fremstilling.
NO2009010C NO2009010I2 (no)	1999-07-02	2009-05-05	Metoksypolyenglykol-epoetin beta beta

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2009010C NO2009010I2 (no)	1999-07-02	2009-05-05	Metoksypolyenglykol-epoetin beta beta

Country Status (51)

Country	Link
US (2)	US6583272B1 (no)
EP (2)	EP1064951B1 (no)
JP (2)	JP3727009B2 (no)
KR (1)	KR100593143B1 (no)
CN (2)	CN1184233C (no)
AR (2)	AR024625A1 (no)
AT (1)	ATE370748T1 (no)
AU (1)	AU736067B2 (no)
BG (1)	BG65449B1 (no)
BR (2)	BR0002276A (no)
CA (1)	CA2310536C (no)
CO (1)	CO5190661A1 (no)
CY (2)	CY1107719T1 (no)
CZ (1)	CZ299516B6 (no)
DE (3)	DE60036053T2 (no)
DK (1)	DK1064951T3 (no)
DO (1)	DOP2000000030A (no)
EA (1)	EA003777B1 (no)
ES (2)	ES2289985T3 (no)
FR (2)	FR2795734B1 (no)
GB (2)	GB2353281B (no)
GC (1)	GC0000197A (no)
GE (1)	GEP20022804B (no)
GT (1)	GT200000109A (no)
HR (1)	HRP20000436B1 (no)
HU (1)	HU226233B1 (no)
ID (1)	ID26447A (no)
IL (1)	IL137056A0 (no)
IS (1)	IS2492B (no)
IT (1)	IT1318606B1 (no)
LU (1)	LU91363I2 (no)
MA (1)	MA26746A1 (no)
MX (1)	MXPA00006547A (no)
MY (1)	MY128500A (no)
NL (1)	NL300289I9 (no)
NO (2)	NO327043B1 (no)
NZ (1)	NZ505454A (no)
OA (1)	OA11442A (no)
PA (1)	PA8497801A1 (no)
PE (1)	PE20010297A1 (no)
PL (1)	PL202758B1 (no)
PT (1)	PT1064951E (no)
RS (1)	RS49928B (no)
SG (1)	SG92717A1 (no)
SI (1)	SI1064951T1 (no)
SK (1)	SK286301B6 (no)
SV (1)	SV2002000120A (no)
TN (1)	TNSN00147A1 (no)
TR (1)	TR200001956A2 (no)
TW (1)	TWI235667B (no)
UY (1)	UY26228A1 (no)

Families Citing this family (231)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2590912T3 (es)	1997-12-08	2016-11-24	Merck Patent Gmbh	Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) *	1998-02-25	2003-06-05	Stephen Gillies	Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) *	1998-04-15	2007-03-01	Emd Lexigen Research Center Corp.	Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
US7304150B1 (en) *	1998-10-23	2007-12-04	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) *	1999-04-13	2008-03-18	The Kenneth S. Warren Institute, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) *	1999-08-09	2002-08-12	Lexigen Pharm Corp	Complejos multiples de citosina-anticuerpo.
US20050202538A1 (en) *	1999-11-12	2005-09-15	Merck Patent Gmbh	Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en)	1999-11-12	2001-05-25	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Erythropoietin forms with improved properties
HUP0204475A2 (en) *	2000-02-11	2003-04-28	Merck Patent Gmbh	Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) *	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
ME00673B (me) *	2000-05-15	2011-12-20	Hoffmann La Roche	Nova farmaceutska smjesa
KR20030064275A (ko) *	2000-06-29	2003-07-31	메르크 파텐트 게엠베하	면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
WO2002032957A1 (en) *	2000-10-16	2002-04-25	Chugai Seiyaku Kabushiki Kaisha	Peg-modified erythropoietin
EP1345628B1 (en) *	2000-12-20	2011-04-13	F. Hoffmann-La Roche AG	Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
AU2002233230B2 (en) *	2000-12-20	2007-02-01	F. Hoffmann-La Roche Ag	Erythropoietin conjugates
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1234583A1 (en) *	2001-02-23	2002-08-28	F. Hoffmann-La Roche Ag	PEG-conjugates of HGF-NK4
RU2003129528A (ru) *	2001-03-07	2005-04-10	Мерк Патент ГмбХ (DE)	Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
DE10112825A1 (de)	2001-03-16	2002-10-02	Fresenius Kabi De Gmbh	HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) *	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
EP1383785B1 (en)	2001-05-03	2011-03-16	Merck Patent GmbH	Recombinant tumor specific antibody and use thereof
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
KR100467751B1 (ko)	2001-12-03	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
DK1454138T3 (da) *	2001-12-04	2012-02-13	Merck Patent Gmbh	Immunocytokiner med moduleret selektivitet
DK2298301T3 (en) *	2001-12-06	2018-10-01	Fibrogen Inc	MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
WO2003078959A2 (en)	2002-03-11	2003-09-25	Ortho Mcneil Pharmaceutical, Inc	Methods for shp1 mediated neuroprotection
EP1552298A4 (en) *	2002-07-01	2006-11-08	Kenneth S Warren Inst Inc	RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
MXPA05000796A (es)	2002-07-24	2005-04-19	Hoffmann La Roche	Aditivos de acidos polialquilenglicolicos.
US7459435B2 (en) *	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US20050176627A1 (en) *	2002-09-09	2005-08-11	Anthony Cerami	Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
BR0314227A (pt)	2002-09-11	2005-10-25	Fresenius Kabi De Gmbh	Derivados de amido de hidroxialquila
US7459436B2 (en) *	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US7388079B2 (en) *	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
WO2004055056A1 (en) *	2002-12-17	2004-07-01	Merck Patent Gmbh	Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7553930B2 (en)	2003-01-06	2009-06-30	Xencor, Inc.	BAFF variants and methods thereof
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en)	2003-03-31	2009-10-27	Xencor, Inc.	Methods for rational pegylation of proteins
US7587286B2 (en)	2003-03-31	2009-09-08	Xencor, Inc.	Methods for rational pegylation of proteins
US7642340B2 (en)	2003-03-31	2010-01-05	Xencor, Inc.	PEGylated TNF-α variant proteins
US7279174B2 (en) *	2003-05-08	2007-10-09	Advanced Cardiovascular Systems, Inc.	Stent coatings comprising hydrophilic additives
CN1820024B (zh) *	2003-05-12	2011-06-22	阿费麦克斯公司	新的聚(乙二醇)修饰的化合物及其用途
AU2004238868B2 (en) *	2003-05-12	2010-01-21	Affymax, Inc.	Peptides that bind to the erythropoietin receptor
US7919118B2 (en) *	2003-05-12	2011-04-05	Affymax, Inc.	Spacer moiety for poly (ethylene glycol) modified peptide based compounds
ATE428727T1 (de)	2003-05-12	2009-05-15	Affymax Inc	Neue, an den erythropoietinrezeptor bindende peptide
CA2527665A1 (en) *	2003-05-30	2004-12-16	Centocor, Inc.	Formation of novel erythropoietin conjugates using transglutaminase
WO2005011587A2 (en) *	2003-07-30	2005-02-10	New Century Pharmaceuticls	Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
WO2005032467A2 (en) *	2003-09-29	2005-04-14	Warren Pharmaceuticals, Inc.	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
EP1675871A2 (en)	2003-10-10	2006-07-05	Xencor Inc.	Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
SI1696947T1 (sl) *	2003-12-19	2014-05-30	F. Hoffmann-La Roche Ag	Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih
EP1548031A1 (en) *	2003-12-22	2005-06-29	Dubai Genetics FZ-LLC	Nature-identical erythropoietin
RU2370276C2 (ru) *	2003-12-31	2009-10-20	Мерк Патент Гмбх	Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
CA2553528C (en) *	2004-01-21	2012-12-04	Nektar Therapeutics Al, Corporation	Method of preparing propionic acid-terminated polymers
ZA200606225B (en) *	2004-02-02	2007-11-28	Ambrx Inc	Modified human four helical bundle polypeptides and their uses
JP5191729B2 (ja)	2004-03-11	2013-05-08	フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
US7253650B2 (en)	2004-05-25	2007-08-07	International Business Machines Corporation	Increase productivity at wafer test using probe retest data analysis
JP2008519858A (ja) *	2004-11-11	2008-06-12	アフィーマックス・インコーポレイテッド	エリスロポエチンレセプターに結合する新規ペプチド
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
BRPI0606934A2 (pt)	2005-01-25	2017-07-11	Cell Therapeutics Inc	Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
US7714114B2 (en) *	2005-02-16	2010-05-11	Nektar Therapeutics	Conjugates of an EPO moiety and a polymer
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) *	2005-09-28	2007-03-29	Anton Haselbeck	Treatment of neurodegenerative disorders
CA2625208A1 (en) *	2005-10-04	2007-04-12	Zymogenetics, Inc.	Production and purification of il-29
US8124095B2 (en) *	2005-10-07	2012-02-28	Armagen Technologies, Inc.	Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) *	2005-10-07	2014-06-03	Armagen Technologies, Inc.	Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) *	2005-10-07	2011-11-08	Armagen Technologies, Inc.	Nucleic acids encoding and methods of producing fusion proteins
AU2006304856A1 (en) *	2005-10-21	2007-04-26	Synageva Biopharma Corp.	Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) *	2005-10-21	2008-07-17	Avigenics, Inc.	Pharmacodynamically enhanced therapeutic proteins
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
EP3222142A1 (en)	2006-02-28	2017-09-27	Kodiak Sciences Inc.	Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
JP5553506B2 (ja)	2006-03-22	2014-07-16	中外製薬株式会社	エリスロポエチン溶液製剤
PL2054074T3 (pl) *	2006-08-04	2015-03-31	Prolong Pharmaceuticals Llc	Zmodyfikowana erytropoetyna
US8759297B2 (en) *	2006-08-18	2014-06-24	Armagen Technologies, Inc.	Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008065372A2 (en) *	2006-11-28	2008-06-05	Nautilus Biotech, S.A.	Modified erythropoietin polypeptides and uses thereof for treatment
TW201307390A (zh) *	2007-02-02	2013-02-16	Amgen Inc	海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
WO2008137066A1 (en) *	2007-05-02	2008-11-13	The Board Of Regents Of The University Of Oklahoma	Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CL2008002053A1 (es) *	2007-07-17	2009-05-22	Hoffmann La Roche	Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
AR067536A1 (es) *	2007-07-17	2009-10-14	Hoffmann La Roche	Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
AU2008282496B2 (en)	2007-07-27	2013-04-04	Armagen Technologies, Inc.	Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP2205280B1 (en) *	2007-09-27	2019-09-04	Amgen Inc.	Pharmaceutical formulations
US8796206B2 (en)	2007-11-15	2014-08-05	Amgen Inc.	Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8101706B2 (en)	2008-01-11	2012-01-24	Serina Therapeutics, Inc.	Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5514736B2 (ja)	2008-01-11	2014-06-04	セリナ・セラピユーテイツクス・インコーポレーテツド	ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
WO2009094551A1 (en)	2008-01-25	2009-07-30	Amgen Inc.	Ferroportin antibodies and methods of use
MX344166B (es)	2008-02-08	2016-12-07	Ambrx Inc	Leptina-polipeptidos modificados y sus usos.
TWI395593B (zh)	2008-03-06	2013-05-11	Halozyme Inc	可活化的基質降解酵素之活體內暫時性控制
KR20130116386A (ko)	2008-04-14	2013-10-23	할로자임, 아이엔씨	히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US9315577B2 (en)	2008-05-01	2016-04-19	Amgen Inc.	Anti-hepcidin antibodies and methods of use
CN102131516B (zh)	2008-06-27	2016-03-16	杜克大学	包含弹性蛋白样肽的治疗剂
BR122012024318A2 (pt)	2008-09-26	2019-07-30	Ambrx, Inc.	Polipeptídeos modificados de eritropoetina animal e seus usos
JP6018753B2 (ja)	2008-11-13	2016-11-02	ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅＧｅｎｅｒａｌＨｏｓｐｉｔａｌＣｏｒｐｏｒａｔｉｏｎ	Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
EA022752B1 (ru)	2008-12-09	2016-02-29	Галозим, Инк.	Длинные растворимые полипептиды рн20 и их использование
CA2748889A1 (en)	2009-03-18	2010-09-23	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
CA2768326C (en)	2009-07-30	2019-01-08	F. Hoffmann-La Roche Ag	Moveable chromatography column separator
WO2011024025A1 (en) *	2009-08-28	2011-03-03	Avesthagen Limited	An erythropoietin analogue and a method thereof
HUE028832T2 (en)	2009-09-17	2017-01-30	Baxalta Inc	Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
EA022396B1 (ru) *	2009-09-23	2015-12-30	Ратиофарм Гмбх	Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин
EP2485761B1 (en)	2009-10-09	2019-02-27	Armagen, Inc.	Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011050333A1 (en)	2009-10-23	2011-04-28	Amgen Inc.	Vial adapter and system
WO2011075185A1 (en)	2009-12-18	2011-06-23	Oligasis	Targeted drug phosphorylcholine polymer conjugates
SG10201502398RA (en)	2010-04-27	2015-05-28	Scil Technology Gmbh	Stable MIA/CD-RAP formulations
SG186094A1 (en)	2010-06-07	2013-01-30	Amgen Inc	Drug delivery device
WO2012012300A2 (en)	2010-07-20	2012-01-26	Halozyme, Inc.	Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
CN103118708B (zh)	2010-09-14	2015-08-26	霍夫曼-拉罗奇有限公司	用于纯化聚乙二醇化的促红细胞生成素的方法
MX347297B (es)	2011-02-02	2017-04-21	Hoffmann La Roche	Soporte para columna de cromatografía.
WO2012109387A1 (en)	2011-02-08	2012-08-16	Halozyme, Inc.	Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
AU2012236573B2 (en)	2011-03-31	2016-06-02	Amgen Inc.	Vial adapter and system
HUE042822T2 (hu)	2011-04-20	2019-07-29	Amgen Inc	Automata befecskendezõ szerkezet
US20130011378A1 (en)	2011-06-17	2013-01-10	Tzung-Horng Yang	Stable formulations of a hyaluronan-degrading enzyme
PL3045187T3 (pl)	2011-10-14	2019-09-30	Amgen Inc.	Wstrzykiwacz i sposób montażu
JP6162707B2 (ja)	2011-10-24	2017-07-12	ハロザイムインコーポレイテッド	抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
AU2012346448B2 (en)	2011-12-02	2017-09-14	Armagen, Inc.	Methods and compositions for increasing arylsulfatase A activity in the CNS
WO2013102144A2 (en)	2011-12-30	2013-07-04	Halozyme, Inc.	Ph20 polypeptede variants, formulations and uses thereof
CN108686203A (zh)	2012-04-04	2018-10-23	哈洛齐梅公司	使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
CN102816227A (zh) *	2012-08-30	2012-12-12	深圳赛保尔生物药业有限公司	回收促红细胞生成素的方法
WO2014062856A1 (en)	2012-10-16	2014-04-24	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
ES2860954T3 (es)	2012-11-21	2021-10-05	Amgen Inc	Dispositivo de administración de fármacos
TWI614041B (zh)	2013-03-15	2018-02-11	安美基公司	用於注射器之匣盒
WO2014152006A2 (en)	2013-03-15	2014-09-25	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
JP6336564B2 (ja)	2013-03-15	2018-06-06	アムゲン・インコーポレーテッド	薬物カセット、自動注入器、および自動注入器システム
US10646664B2 (en)	2013-03-15	2020-05-12	Amgen Inc.	Body contour adaptable autoinjector device
WO2014149357A1 (en)	2013-03-22	2014-09-25	Amgen Inc.	Injector and method of assembly
TW201534726A (zh)	2013-07-03	2015-09-16	Halozyme Inc	熱穩定ｐｈ２０玻尿酸酶變異體及其用途
WO2015035342A2 (en)	2013-09-08	2015-03-12	Oligasis Llc	Factor viii zwitterionic polymer conjugates
CA3168888A1 (en)	2013-10-24	2015-04-30	Amgen Inc.	Drug delivery system with temperature-sensitive control
SG11201602876WA (en)	2013-10-24	2016-05-30	Amgen Inc	Injector and method of assembly
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
AU2015256082C1 (en)	2014-05-07	2020-09-10	Amgen Inc.	Autoinjector with shock reducing elements
CN111840696B (zh)	2014-06-03	2022-12-20	安姆根有限公司	可控制药物递送系统和使用方法
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
PT3186281T (pt)	2014-08-28	2019-07-10	Halozyme Inc	Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
US10323088B2 (en)	2014-09-22	2019-06-18	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
BR112017007765B1 (pt)	2014-10-14	2023-10-03	Halozyme, Inc	Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EP3206739B1 (en)	2014-10-14	2021-12-01	Amgen Inc.	Drug injection device with visual and audio indicators
KR20210013299A (ko)	2014-10-17	2021-02-03	코디악 사이언시스 인코포레이티드	부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
EP3848072A1 (en)	2014-12-19	2021-07-14	Amgen Inc.	Drug delivery device with proximity sensor
US10538589B2 (en)	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
JP6484345B2 (ja)	2015-02-17	2019-03-20	アムジエン・インコーポレーテツド	固定及び／または戻りが真空によって支援された薬物送達装置
WO2016138434A1 (en)	2015-02-27	2016-09-01	Amgen Inc.	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
JP7082568B2 (ja)	2015-12-09	2022-06-08	アムジエン・インコーポレーテツド	信号伝達キャップ付き自動注射器
KR20250057128A (ko)	2015-12-30	2025-04-28	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
DK3429663T3 (da)	2016-03-15	2020-09-28	Amgen Inc	Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
CN105820232B (zh) *	2016-04-08	2019-05-17	昂德生物药业有限公司	单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en)	2016-05-13	2022-12-22	Amgen Inc.	Vial sleeve assembly
WO2017200989A1 (en)	2016-05-16	2017-11-23	Amgen Inc.	Data encryption in medical devices with limited computational capability
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en)	2016-07-01	2025-03-12	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
KR102470282B1 (ko)	2016-07-15	2022-11-24	에프. 호프만-라 로슈 아게	Ｐｅｇ화 에리트로포이에틴을 정제하기 위한 방법
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
US20200261643A1 (en)	2016-10-25	2020-08-20	Amgen Inc.	On-body injector
AU2018210301A1 (en)	2017-01-17	2019-08-01	Amgen Inc.	Injection devices and related methods of use and assembly
WO2018151890A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
CA3052204A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Insertion mechanism for drug delivery device
EP3592403B1 (en)	2017-03-06	2025-08-20	Amgen Inc.	Drug delivery device with activation prevention feature
US11571511B2 (en)	2017-03-07	2023-02-07	Amgen Inc.	Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en)	2017-03-09	2023-05-11	Amgen Inc.	Insertion mechanism for drug delivery device
EP3570871B1 (en)	2017-03-20	2020-11-18	H. Hoffnabb-La Roche Ag	Method for in vitro glycoengineering of an erythropoiesis stimulating protein
ES3023742T3 (en)	2017-03-28	2025-06-03	Amgen Inc	Plunger rod and syringe assembly system
US11590294B2 (en)	2017-06-08	2023-02-28	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja)	2017-06-08	2023-01-06	アムジエン・インコーポレーテツド	トルク駆動式薬物送達デバイス
CA3177086A1 (en)	2017-06-22	2018-12-27	Catalyst Biosciences, Inc.	Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
JP7195276B2 (ja)	2017-06-22	2022-12-23	アムジエン・インコーポレーテツド	デバイス起動による衝突／衝撃の低減
WO2018237225A1 (en)	2017-06-23	2018-12-27	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en)	2017-07-14	2023-11-01	Amgen Inc	Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja)	2017-07-21	2025-03-19	アムジエン・インコーポレーテツド	薬物容器のためのガス透過性シーリング部材及び組立方法
US11617837B2 (en)	2017-07-25	2023-04-04	Amgen Inc.	Drug delivery device with gear module and related method of assembly
MA49676A (fr)	2017-07-25	2020-06-03	Amgen Inc	Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567B1 (en)	2017-08-18	2026-02-18	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
WO2019070472A1 (en)	2017-10-04	2019-04-11	Amgen Inc.	FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
ES2971450T3 (es)	2017-10-06	2024-06-05	Amgen Inc	Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en)	2017-10-09	2022-10-11	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en)	2017-11-03	2024-12-01	Amgen Inc	Systems and approaches for sterilizing a drug delivery device
EP3706830B1 (en)	2017-11-06	2024-08-07	Amgen Inc.	Drug delivery device with placement and flow sensing
EP3707075A1 (en)	2017-11-06	2020-09-16	Amgen Inc.	Fill-finish assemblies and related methods
MA50557A (fr)	2017-11-10	2020-09-16	Amgen Inc	Pistons pour dispositifs d'administration de médicament
MX2020005066A (es)	2017-11-16	2020-08-20	Amgen Inc	Autoinyector con deteccion de detencion y punto final.
JP7370969B2 (ja)	2017-11-16	2023-10-30	アムジエン・インコーポレーテツド	薬物送達デバイスの扉ラッチ機構
WO2019129876A1 (en)	2017-12-29	2019-07-04	F. Hoffmann-La Roche Ag	Process for providing pegylated protein composition
US20200362002A1 (en)	2017-12-29	2020-11-19	Hoffmann-La Roche Inc.	Process for providing pegylated protein composition
WO2019129877A1 (en)	2017-12-29	2019-07-04	F. Hoffmann-La Roche Ag	Process for providing pegylated protein composition
EP3758737A4 (en)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
US20190351031A1 (en)	2018-05-16	2019-11-21	Halozyme, Inc.	Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
MA53375A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
CA3103681A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
US12303677B2 (en)	2018-07-24	2025-05-20	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
CA3103105A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
DK3613486T3 (da) *	2018-08-24	2021-01-04	Uga Biopharma Gmbh	Metode og anlæg til rengøring af epo og/eller et epo-derivat
US20210346601A1 (en)	2018-09-24	2021-11-11	Amgen Inc.	Interventional dosing systems and methods
CA3110371A1 (en)	2018-09-28	2020-04-02	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en)	2018-10-02	2021-08-11	Amgen Inc.	Injection systems for drug delivery with internal force transmission
US12151089B2 (en)	2018-10-05	2024-11-26	Amgen Inc.	Drug delivery device having dose indicator
TW202541859A (zh)	2018-10-15	2025-11-01	美商安進公司	具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en)	2018-10-15	2020-04-23	Amgen Inc.	Platform assembly process for drug delivery device
MA54048A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
EP3873563A1 (en)	2018-11-01	2021-09-08	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
US11613744B2 (en)	2018-12-28	2023-03-28	Vertex Pharmaceuticals Incorporated	Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3123872A1 (en)	2018-12-28	2020-07-02	Catalyst Biosciences, Inc.	Modified urokinase-type plasminogen activator polypeptides and methods of use
AU2020263289B2 (en)	2019-04-24	2025-05-22	Amgen Inc.	Syringe sterilization verification assemblies and methods
WO2021041067A2 (en)	2019-08-23	2021-03-04	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
US20230331798A1 (en)	2020-09-22	2023-10-19	Jecho Laboratories, Inc.	Glycosylation-modified erythopoietin and use thereof
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction
CN117279929A (zh)	2021-05-10	2023-12-22	凯奥目生物科学株式会社	抗体组合物的纯化方法
JP2024523779A (ja)	2021-05-21	2024-07-02	アムジェンインコーポレイテッド	薬物容器用の充填レシピを最適化する方法
WO2023209074A1 (en)	2022-04-28	2023-11-02	Institut National de la Santé et de la Recherche Médicale	Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en)	2022-11-02	2024-05-10	F. Hoffmann-La Roche Ag	Method for producing glycoprotein compositions
CN116492448A (zh) *	2023-04-12	2023-07-28	深圳赛保尔生物药业有限公司	负载peg-epo及间充质干细胞的组合物、药物及其制备方法
WO2025227129A2 (en)	2024-04-25	2025-10-30	Starrock Pharma Llc	Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2026030152A1 (en)	2024-07-29	2026-02-05	Amgen Inc.	System and method for assessing transferability of a fill recipe

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
KR850004274A (ko) *	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en)	1989-01-23	1990-02-20	Cetus Corporation	Preparation of a polymer/interleukin-2 conjugate
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) *	1992-06-11	1997-10-07	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en)	1992-12-09	1995-07-26	Ortho Pharma Corp	Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
CN1057534C (zh) *	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
US5643575A (en) *	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5919455A (en) *	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ES2093593T1 (es) *	1995-05-05	1997-01-01	Hoffmann La Roche	Proteinas obesas (ob) recombinantes.
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) *	1996-05-15	2000-02-15	Hoffmann-La Roche Inc.	Pegylated obese (ob) protein compositions
TW517067B (en) *	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
ES2208798T3 (es) *	1997-09-01	2004-06-16	Aventis Pharma Deutschland Gmbh	Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
EP1135493A2 (en)	1998-11-30	2001-09-26	Eli Lilly And Company	Erythropoietic compounds
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) *	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
WO2001068141A2 (en)	2000-03-17	2001-09-20	Maxygen Aps	Dispersions of polypeptide conjugates
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
ME00673B (me) *	2000-05-15	2011-12-20	Hoffmann La Roche	Nova farmaceutska smjesa

2000
- 2000-06-23 CZ CZ20002386A patent/CZ299516B6/cs not_active IP Right Cessation
- 2000-06-27 SK SK987-2000A patent/SK286301B6/sk not_active IP Right Cessation
- 2000-06-27 US US09/604,938 patent/US6583272B1/en not_active Expired - Lifetime
- 2000-06-28 PT PT00113115T patent/PT1064951E/pt unknown
- 2000-06-28 DK DK00113115T patent/DK1064951T3/da active
- 2000-06-28 HR HR20000436A patent/HRP20000436B1/xx not_active IP Right Cessation
- 2000-06-28 PE PE2000000654A patent/PE20010297A1/es not_active IP Right Cessation
- 2000-06-28 AT AT00113115T patent/ATE370748T1/de active
- 2000-06-28 NZ NZ505454A patent/NZ505454A/en not_active IP Right Cessation
- 2000-06-28 ID IDP20000533D patent/ID26447A/id unknown
- 2000-06-28 SI SI200030963T patent/SI1064951T1/sl unknown
- 2000-06-28 TR TR2000/01956A patent/TR200001956A2/xx unknown
- 2000-06-28 DE DE60036053T patent/DE60036053T2/de not_active Expired - Lifetime
- 2000-06-28 EP EP00113115A patent/EP1064951B1/en not_active Expired - Lifetime
- 2000-06-28 CA CA002310536A patent/CA2310536C/en not_active Expired - Lifetime
- 2000-06-28 IL IL13705600A patent/IL137056A0/xx active Protection Beyond IP Right Term
- 2000-06-28 DE DE122007000064C patent/DE122007000064I2/de active Active
- 2000-06-28 ES ES00113115T patent/ES2289985T3/es not_active Expired - Lifetime
- 2000-06-28 AU AU42744/00A patent/AU736067B2/en not_active Expired
- 2000-06-28 EP EP07010693A patent/EP1839676A3/en not_active Withdrawn
- 2000-06-28 NO NO20003372A patent/NO327043B1/no not_active IP Right Cessation
- 2000-06-28 DO DO2000000030A patent/DOP2000000030A/es unknown
- 2000-06-28 RS YUP-407/00A patent/RS49928B/sr unknown
- 2000-06-29 CN CNB001078895A patent/CN1184233C/zh not_active Expired - Lifetime
- 2000-06-29 AR ARP000103318A patent/AR024625A1/es active IP Right Grant
- 2000-06-29 GE GEAP20005430A patent/GEP20022804B/en unknown
- 2000-06-29 CO CO00048963A patent/CO5190661A1/es active IP Right Grant
- 2000-06-29 MY MYPI20002954A patent/MY128500A/en unknown
- 2000-06-29 CN CNB2004100036029A patent/CN1283664C/zh not_active Expired - Lifetime
- 2000-06-29 PA PA20008497801A patent/PA8497801A1/es unknown
- 2000-06-29 GT GT200000109A patent/GT200000109A/es unknown
- 2000-06-29 SG SG200003658A patent/SG92717A1/en unknown
- 2000-06-30 SV SV2000000120A patent/SV2002000120A/es active IP Right Grant
- 2000-06-30 TW TW089112948A patent/TWI235667B/zh not_active IP Right Cessation
- 2000-06-30 MX MXPA00006547A patent/MXPA00006547A/es active IP Right Grant
- 2000-06-30 IT IT2000MI001479A patent/IT1318606B1/it active
- 2000-06-30 MA MA26014A patent/MA26746A1/fr unknown
- 2000-06-30 KR KR1020000036976A patent/KR100593143B1/ko not_active Expired - Lifetime
- 2000-06-30 DE DE10031839A patent/DE10031839A1/de not_active Ceased
- 2000-06-30 GB GB0016205A patent/GB2353281B/en not_active Expired - Lifetime
- 2000-06-30 OA OA1200000197A patent/OA11442A/fr unknown
- 2000-06-30 TN TNTNSN00147A patent/TNSN00147A1/fr unknown
- 2000-06-30 ES ES200001625A patent/ES2191511B1/es not_active Expired - Fee Related
- 2000-06-30 HU HU0002553A patent/HU226233B1/hu active Protection Beyond IP Right Term
- 2000-06-30 BG BG104570A patent/BG65449B1/bg unknown
- 2000-06-30 IS IS5554A patent/IS2492B/is unknown
- 2000-06-30 GB GB0400086A patent/GB2393960C/en not_active Expired - Lifetime
- 2000-06-30 UY UY26228A patent/UY26228A1/es not_active IP Right Cessation
- 2000-07-02 GC GCP2000749 patent/GC0000197A/en active
- 2000-07-03 BR BR0002276-4A patent/BR0002276A/pt not_active IP Right Cessation
- 2000-07-03 BR BRPI0002276A patent/BRPI0002276B8/pt unknown
- 2000-07-03 PL PL341187A patent/PL202758B1/pl not_active IP Right Cessation
- 2000-07-03 JP JP2000201525A patent/JP3727009B2/ja not_active Expired - Lifetime
- 2000-07-03 FR FR0008609A patent/FR2795734B1/fr not_active Expired - Lifetime
- 2000-07-03 EA EA200000607A patent/EA003777B1/ru not_active IP Right Cessation
2002
- 2002-11-14 US US10/293,551 patent/US20030120045A1/en not_active Abandoned
2003
- 2003-12-17 JP JP2003419520A patent/JP2004155787A/ja active Pending
2006
- 2006-09-25 AR ARP060104175A patent/AR055650A2/es unknown
2007
- 2007-08-23 CY CY20071101097T patent/CY1107719T1/el unknown
- 2007-09-05 NL NL300289C patent/NL300289I9/nl unknown
- 2007-09-06 CY CY200700021C patent/CY2007021I2/el unknown
- 2007-09-12 LU LU91363C patent/LU91363I2/fr unknown
- 2007-10-19 FR FR07C0051C patent/FR07C0051I2/fr active Active
2009
- 2009-05-05 NO NO2009010C patent/NO2009010I2/no unknown

Also Published As

Publication number	Publication date
AU736067B2 (en)	2001-07-26
JP3727009B2 (ja)	2005-12-14
IT1318606B1 (it)	2003-08-27
HUP0002553A3 (en)	2005-11-28
JP2004155787A (ja)	2004-06-03
NL300289I2 (nl)	2010-02-01
SK9872000A3 (en)	2002-06-04
DE60036053T2 (de)	2008-01-03
DOP2000000030A (es)	2002-07-15
ES2191511A1 (es)	2003-09-01
KR100593143B1 (ko)	2006-06-26
GB0016205D0 (en)	2000-08-23
SG92717A1 (en)	2002-11-19
DE122007000064I2 (de)	2010-03-25
YU40700A (sh)	2003-12-31
MA26746A1 (fr)	2004-12-20
CY2007021I1 (el)	2009-11-04
TWI235667B (en)	2005-07-11
GB2393960B (en)	2004-08-04
PE20010297A1 (es)	2001-03-07
CA2310536A1 (en)	2001-01-02
LU91363I2 (fr)	2007-11-12
HK1033328A1 (en)	2001-08-24
FR2795734B1 (fr)	2005-09-30
NO20003372D0 (no)	2000-06-28
EP1839676A2 (en)	2007-10-03
CO5190661A1 (es)	2002-08-29
NL300289I1 (nl)	2007-11-01
HUP0002553A2 (en)	2001-03-28
CN1515590A (zh)	2004-07-28
NO327043B1 (no)	2009-04-06
ES2191511B1 (es)	2005-01-01
GB2393960A (en)	2004-04-14
EA200000607A1 (ru)	2001-02-26
PL341187A1 (en)	2001-01-15
DK1064951T3 (da)	2007-10-08
CY2007021I2 (el)	2009-11-04
ATE370748T1 (de)	2007-09-15
SV2002000120A (es)	2002-01-31
LU91363I9 (no)	2018-12-31
ID26447A (id)	2001-01-04
GT200000109A (es)	2001-12-21
HRP20000436A2 (en)	2001-06-30
IL137056A0 (en)	2001-06-14
TR200001956A2 (tr)	2001-01-22
CA2310536C (en)	2007-09-11
US20030120045A1 (en)	2003-06-26
GB2353281B (en)	2004-06-09
IS2492B (is)	2009-02-15
ITMI20001479A0 (it)	2000-06-30
NO2009010I2 (no)	2014-06-02
UY26228A1 (es)	2000-10-31
TNSN00147A1 (fr)	2005-11-10
GEP20022804B (en)	2002-09-25
MY128500A (en)	2007-02-28
CY1107719T1 (el)	2010-07-28
PT1064951E (pt)	2007-09-10
NZ505454A (en)	2001-12-21
AR055650A2 (es)	2007-08-29
SK286301B6 (en)	2008-07-07
FR07C0051I2 (fr)	2008-05-09
HU0002553D0 (en)	2000-08-28
CZ299516B6 (cs)	2008-08-20
KR20010049676A (ko)	2001-06-15
EP1064951A2 (en)	2001-01-03
GB2393960C (en)	2012-08-29
BG65449B1 (bg)	2008-08-29
GB2353281A (en)	2001-02-21
RS49928B (sr)	2008-09-29
BRPI0002276B8 (pt)	2021-05-25
EP1839676A3 (en)	2008-09-03
PA8497801A1 (es)	2001-12-14
CN1184233C (zh)	2005-01-12
MXPA00006547A (es)	2004-10-28
EP1064951A3 (en)	2002-03-20
AU4274400A (en)	2001-01-04
AR024625A1 (es)	2002-10-16
ITMI20001479A1 (it)	2001-12-30
DE60036053D1 (de)	2007-10-04
NO2009010I1 (no)	2009-05-25
SI1064951T1 (sl)	2007-12-31
CN1280137A (zh)	2001-01-17
NL300289I9 (nl)	2019-08-21
CN1283664C (zh)	2006-11-08
FR2795734A1 (fr)	2001-01-05
GB0400086D0 (en)	2004-02-04
DE122007000064I1 (de)	2008-01-03
BR0002276A (pt)	2001-12-11
JP2001064300A (ja)	2001-03-13
DE10031839A1 (de)	2001-02-01
EP1064951B1 (en)	2007-08-22
ES2289985T3 (es)	2008-02-16
BG104570A (en)	2001-09-28
HRP20000436B1 (en)	2008-01-31
BRPI0002276B1 (pt)	2019-05-14
HK1068354A1 (en)	2005-04-29
CZ20002386A3 (cs)	2002-04-17
US6583272B1 (en)	2003-06-24
GC0000197A (en)	2006-03-29
OA11442A (fr)	2004-04-28
EA003777B1 (ru)	2003-08-28
IS5554A (is)	2001-01-02
FR07C0051I1 (no)	2007-12-14
PL202758B1 (pl)	2009-07-31
HU226233B1 (en)	2008-07-28

Legal Events

Date	Code	Title	Description
2014-06-02	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: METOKSYPOLYENGLYKOL-EPOETIN BETA BETA (MIRCERA); NAT. REGISTRATION NO/DATE: EU107400001-16 20070903; FIRST REGISTRATION: GB EU107400001-16 20070720 Spc suppl protection certif: 2009010 Filing date: 20090505 Extension date: 20220720
2018-08-20	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: METOKSYPOLYENGLYKOL-EPOETIN BETA BETA; REG. NO/DATE: EU107400001-16 20070903 Spc suppl protection certif: 2009010 Filing date: 20090505 Extension date: 20220724
2020-07-13	MK1K	Patent expired
2022-08-15	SPCX	Expiry of an spc	Spc suppl protection certif: 2009010

Publication	Publication Date	Title
DK1064951T3 (da)	2007-10-08	Erythropoietinderivater
IS2116B (is)	2006-06-15	4-fenyl-pyridin afleiður
NO20021077L (no)	2002-03-05	Amino-triazolopyridin-derivater
DE60009747D1 (de)	2004-05-13	Admantan-derivate
DE50010060D1 (de)	2005-05-19	Thiazolylamid-derivate
IS6128A (is)	2001-10-26	13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da)	2004-12-20	5-phenyl-pyrimidinderivater
ATE338021T1 (de)	2006-09-15	Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20021803D0 (no)	2002-04-17	Isoksazolkarboksamid-derivater
ATE257148T1 (de)	2004-01-15	Propargyletherderivate
ATE374747T1 (de)	2007-10-15	Monofluoralkylderivate
DK1154988T3 (da)	2004-11-22	Mevinolinderivater
ATE293592T1 (de)	2005-05-15	Resorcinderivate
ATE254598T1 (de)	2003-12-15	4-hydroxybiphenylhydrazid-derivate
DK1187815T3 (da)	2006-06-19	4-phenyl-pyrimidinderivater
DE60025348D1 (de)	2006-03-30	Ethansulfonyl-piperidin-derivate
NO20020212L (no)	2002-01-15	3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no)	2002-06-14	Syklopentenon-derivater
DE60001736D1 (de)	2003-04-24	1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de)	2004-07-15	1-cycloalkylpyrazolyl-benzoyl-derivate